| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0045 | 1 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.0045 | 1 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.0043 | 1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.00085 | 1 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.00074 | 1 |